AKT3 and colorectal carcinoma: Combined, our data indicates that AKT3 and FRMD6 expression strongly associate with EMT and that FRMD6 can be used as a surrogate marker for EMT and epithelial AKT3 expression levels to predict prognosis in CRC patients.